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Background: The combined predictive value of plasma uric acid and primary tumor volume in nasopharyngeal
carcinoma (NPC) patients receiving intensity modulated radiation therapy (IMRT) has not yet been determined.
Methods: In this retrospective study, plasma uric acid level was measured after treatment in 130 histologically-proven
NPC patients treated with IMRT. Tumor volume was calculated from treatment planning CT scans. Overall (OS),
progression-free (PFS) and distant metastasis-free (DMFS) survival were compared using Kaplan-Meier analysis and the
log rank test, and Cox multivariate and univariate regression models were created.
Results: Patients with a small tumor volume (<27 mL) had a significantly better DMFS, PFS and OS than patients
with a large tumor volume. Patients with a high post-treatment plasma uric acid level (>301 μmol/L) had a better
DMFS, PFS and OS than patients with a low post-treatment plasma uric acid level. Patients with a small tumor
volume and high post-treatment plasma uric acid level had a favorable prognosis compared to patients with a large
tumor volume and low post-treatment plasma uric acid level (7-year overall OS, 100% vs. 48.7%, P <0.001 and PFS,
100% vs. 69.5%, P <0.001).
Conclusions: Post-treatment plasma uric acid level and pre-treatment tumor volume have predictive value for
outcome in NPC patients receiving IMRT. NPC patients with a large tumor volume and low post-treatment plasma
uric acid level may benefit from additional aggressive treatment after IMRT.
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Nasopharyngeal carcinoma (NPC) is a common epithelial
malignancy in southern China [1,2]. NPC has a distinct
epidemiology, etiology and clinical course compared
to other head and neck squamous cell carcinomas. In-
tensity modulated radiotherapy (IMRT) has gradually
replaced two-dimensional conventional radiotherapy
(2D-CRT) as the primary means of radiotherapy, and
has led to superior locoregional control and improved
long-term survival rates in NPC patients. The 3-year* Correspondence: huwh@sysucc.org.cn
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reproduction in any medium, provided the oroverall survival (OS) rate for NPC patients treated by
IMRT combined with cisplatin concurrent chemother-
apy is currently 85-90% [3-6].
Uric acid is the end product of purine metabolism.
Radiotherapy is associated with increased oxidative dam-
age to DNA [7]. A high plasma uric acid level may occur
due to increased purine metabolism by xanthine oxidase,
as a consequence of RNA-DNA breakdown in patients
receiving radiotherapy [7]. The plasma uric acid level
may be used as an indicator of radiosensitivity.
Recently, a number of reports have demonstrated the
prognostic significance of the primary gross tumor vol-
ume for predicting local control, distant metastasis and
overall survival in NPC patients receiving IMRT [8];
however, the prognostic value of plasma uric acid levels,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tumor volume, remain unknown in NPC patients receiv-
ing IMRT .
In this study, the clinical records of NPC patients
treated with radical IMRT at Sun Yat-sen University
Cancer Center were retrospectively analyzed. The pre-
treatment tumor volumes and post-treatment plasma uric
acid levels were evaluated, with the aim of establishing
prognostic subsets for the selection of appropriate treat-
ment strategies in NPC.
Materials and methods
Clinical data
The study included 130 pathologically diagnosed NPC pa-
tients without distant metastases, who were treated with
definitive-intent IMRT techniques at the Department of
Radiation, Sun Yat-sen University Cancer Center between
December, 2003 and December, 2005. The entry criteria
consisted of: 1) a recorded post-treatment plasma uric acid
level; 2) complete clinical data; 3) treated with IMRT; and
4) normal renal function.
The routine pre-treatment evaluation included a blood
test, pre-treatment and post-treatment biochemical tests,
full clinical examination, nasopharyngeal fiber mirror in-
spection, chest X-ray, ultrasound imaging of the abdom-
inal region, nasopharyngeal MRI scan, general bone scan
and Epstein-Barr virus (EBV) EA-IgA test. All patients
with N3 disease also received a chest CT scan. This
study was approved by the Research Ethics Committee
of the Sun Yat-sen University Cancer Center.
We have check medical records of the patients in our
study, and found that none of them had a hyperuricemia
or Gout history. We found 45 patients had the record of
Plasma uric acid level measured before treatment and
none of them with hyperuricemia.
Radiotherapy
Radiation was delivered with a linear accelerator (Varian,
Palo Alto, CA, USA) using 6 MV photons. IMRT was de-
livered with a dynamic multileaf intensity-modulating
collimator (PEACOCK-MIMiC system) using a slice-
by-slice arc rotation approach. In accordance with our in-
stitutional treatment protocol, the primary tumor and
upper neck above the cricoid cartilage (including levels II,
III and VA) were treated with IMRT, whereas the lower
neck (including levels IV and VB) and supraclavicular fos-
sae were treated with a single anterior split field by conven-
tional radiotherapy.
The CTV1 was defined as the nasopharyngeal gross
tumor volume plus a 5–10-mm margin to encompass
the high-risk sites of microscopic extension and the
whole nasopharynx mucosa plus a 5-mm submucosal
volume. The CTV2 was defined by adding a 5–10-mm
margin to the CTV1 to encompass the low-risk sites ofmicroscopic extension, the level of the lymph node lo-
cated, and the neck area.
The prescribed doses were determined according
to the simultaneous modulated accelerated radiation
therapy boost technique [9]. The prescribed dose was
68 Grays (Gy) over 30 fractions to the nasopharyngeal
gross target volume, 60 Gy/30 fractions to the define
(CTV1), 54 Gy/30 fractions to the define (CTV2), and
60–66 Gy/30 fractions to the positive cervical lymph
nodes. The prescribed dose to the lower neck and the
supraclavicular fossae (irradiated with conventional
radiotherapy) was 50 Gy/25 fractions for prophylactic
intent and 60–66 Gy/30-33 fractions for therapeutic in-
tent. Treatment plan was approved to meet the evalu-
ation criterion of our institution previously reported by
Xiao et al., [3,8].
Chemotherapy
In total, 93 of the 130 (71.5%) NPC patients received
chemoradiotherapy; 86 of the 106 (81.1%) stage III-IVa
patients received chemoradiotherapy. A total of 83
patients received concurrent chemotherapy with cis-
platin (intravenous infusion of 30 mg/m2 every week,
or intravenous infusion of 100 mg/m2 every 3 weeks)
or paclitaxel (intravenous infusion of 30 mg/m2 every
week). Reasons for deviation from the guidelines in-
cluded age or organ dysfunction that suggested intoler-
ance to chemotherapy.
Pre-treatment tumor volume measurement
All target volumes (gross tumor volume, CTV1 and
CTV2) and the critical adjacent organs were outlined
slice-by-slice on the axial fused plain and contrast-
enhanced CT images in the treatment planning system
in combination with the MR images. The treatment
plans were evaluated and approved by three or four radi-
ation oncologists specializing in NPC. The treatment
planning system was used to automatically reconstruct a
three-dimensional image and calculate the volume of the
tumor targets and critical organs prior to treatment. In
this study, the tumor volume included the gross volume
of the primary tumor and enlarged lymph nodes.
Measurement of post-treatment plasma uric acid level
Plasma uric acid level was measured after RT using an
Hitachi 7080 automatic biochemical analyzer.
Observation and follow-up
Patients returned for follow-up appointments at least
every three months during the first two years and every
six months thereafter, until death. Every patient under-
went an EBV EA-IgA test, routine hematological and
biochemistry profiles, chest X-ray, ultrasound imaging
of the abdominal region, and MRI or CT scan of the
Table 1 Baseline clinicopathological characteristics of the
130 nasopharyngeal cancer patients





< 45 years 61 53.1
≥ 45 years 69 46.9
Karnofsky performance score
< 90 11 8.5








Radiotherapy alone 37 71.5
Chemoradiotherapy 93 28.5
* According to the 7th edition of the American Joint Committee on Cancer/
International Union Against Cancer staging system.
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underwent chest and abdominal CT scans, and general
bone or PET-CT scans. Follow-up times were calculated
from the end of radiotherapy until first event.
The date of last follow-up was July 1, 2012; median
follow-up for the entire cohort was 87 months (range,
6–101 months). The following endpoints (time to first
defining event) were assessed: overall survival (OS),
progression-free survival (PFS) and distant metastasis-
free survival (DMFS).
Statistical analysis
OS, DMFS and PFS were calculated by the Kaplan-
Meier method and analyzed using the log-rank test
with SPSS 19.0 (SPSS, Chicago, IL, USA). The Cox re-
gression model was constructed by forward selection
(introduction = 0.05; removal = 0.1); P < 0.05 was
considered statistically significant. Receiver operating
characteristic (ROC) curve analysis was applied to de-
termine the optimal tumor volume cutoff point.
Results
Patient characteristics and outcome
The median age of the NPC patients was 44 years
(range, 18–76 years). Eighty eight of the 130 (67.7%) pa-
tients were men. Ninety-seven (91.9%) patients had good
performance status (Karnofsky performance score ≧ 90).
Thirty seven (28.5%) patients received radiotherapy
alone, and Ninety three (71.5%) patients received com-
bined chemoradiotherapy. The T and N stage distribu-
tions of the 130 patients according to the 7th edition of
the UICC staging criteria are shown in Table 1.
OS data was collected for 130 patients up to July 1,
2012, with a median follow-up time of 87 months
(range, 6–101 months) and follow-up rate of 100%. By
the end of follow-up, 23/130 (17.7%) patients had devel-
oped recurrence or metastasis; 4 (3.1%) had developed
local recurrence, 9 (6.9%) had developed regional recur-
rence, and 10 (7.7%) had developed distant metastases
including three cases of pulmonary metastasis, three
cases of bone metastasis, one case of liver metastasis,
one case of brain metastasis, and one case of pleural and
peritoneal metastasis. In total, 21/130 (11.0%) of the pa-
tients died, 20 (9.6%) of whom died due to tumor pro-
gression. For the entire cohort, the 7-year OS, PFS and
DMFS rates were 81.7%, 87.5% and 91.9%, respectively.
Relationship between tumor volume and patient outcome
The median pre-treatment tumor volume for the 130
patients was 37.33 mL (range, 1.62–228.05 mL). Using
ROC curve analysis, it was determined that 27 mL was
an appropriate cutoff point for OS. The 7-year DMFS,
PFS and OS rates for patients with a pre-treatment
tumor volume smaller than 27 mL were significantlyhigher than patients with a pre-treatment tumor volume
equal to or larger tumor volume than 27 mL (OS, 97.8%
vs. 71.1%, P < 0.001; PFS, 95.7% vs. 81.6%, P =0.017; DMFS,
100% vs. 86.2%, P = 0.009; Figure 1).
Relationship between plasma uric acid and patient
outcome
The median post-treatment plasma uric acid level for
all patients was 301 μmol/L (range, 78–624 μmol/l).
The 7-year DMFS, PFS and OS rates for patients with
a post-treatment plasma uric acid level above the me-
dian value were significantly higher than patients with
a post-treatment plasma uric acid level equal to or
below 301 μmol/L (OS, 93.7% vs. 66.3%, P < 0.001;
PFS, 90.5% vs. 77.2%, P = 0.002, DMFS, 97% vs. 86.1%,
P = 0.026; Figure 2).
Relationship of combined post-treatment plasma uric acid
level and tumor volume with patient outcome
Patients were divided into three subgroups according
to the post-treatment plasma uric acid levels and
pre-treatment tumor volumes: (1) small tumor volume
(< 27 mL) and high post-treatment plasma uric acid
level (>301 μmol/L; n = 28 patients); (2) small pre-
treatment tumor volume (< 27 mL) and low post-
treatment plasma uric acid level, or large pre-treatment
tumor volume (≥ 27 mL) and high post-treatment plasma
Figure 1 Kaplan-Meier overall survival, progression-free survival and distant metastasis-free survival curves for 130 nasopharyngeal
cancer patients treated with IMRT stratified by pre-treatment primary tumor volume.
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pre-treatment tumor volume (≥ 27 mL) and low post-
treatment plasma uric acid level (≤301 μmol/L; n = 35
patients). The 7-year OS rates for these three subgroups
were 100%, 90.5% and 48.7%, respectively (p<0.001). The
7-year PFS rates in the three subgroups were 100%, 92.8%
and 69.2%, respectively (p<0.001). The 7-year DMFS rates
in the three subgroups were 100%, 96.4% and 77.7%, re-
spectively (p=0.001) (Figure 3).
Multivariate analysis
Multivariate analysis was performed to adjust for various
prognostic factors. Post-treatment plasma uric acid level
and pre-treatment tumor volume were the only independ-
ent predictors of OS. Both the post-treatment plasma uric
acid level and tumor classification were identified as inde-
pendent prognostic factors for PFS. Age, sex and node
classification had no statistically significant effect on sur-
vival (Tables 2 and 3).Figure 2 Kaplan-Meier overall survival, progression-free survival and
cancer patients treated with IMRT stratified by post-treatment plasmaDiscussion
Various studies have attempted to identify predictive fac-
tors for poor patient outcome in NPC, by analyzing trad-
itional clinical, pathological and molecular biomarkers as
probable prognostic factors. Radiotherapy is associated
with increased oxidative damage to DNA [10]. A high
plasma uric acid level may occur in patients undergoing
radiotherapy due to increased purine metabolism by
xanthine oxidase, as a consequence of tumor cell RNA-
DNA breakdown [11]. Patients with poorly differentiated
tumors, such as Burkitt's lymphoma, may have an ele-
vated uric acid level as a result of the rapid destruction of
malignant cells. The plasma uric acid level can be used as
an indicator of radiosensitivity. However, the predictive
value of plasma uric acid levels has not previously been
investigated in NPC patients treated with IMRT.
In the present study of a relatively large cohort of
NPC patients treated with IMRT, we demonstrated that
the post-treatment plasma uric acid level was a strongdistant metastasis-free survival curves for 130 nasopharyngeal
uric acid level.
Figure 3 Kaplan-Meier overall survival, progression-free survival and distant metastasis-free survival for 130 nasopharyngeal cancer
patients treated with IMRT, stratified according a combination of pre-treatment primary tumor volume (TV) and post-treatment
plasma uric acid (UA). S-TV/H-UA indicates a small tumor volume (< 27 mL) and high post-treatment plasma uric acid level (>301 μmol/L);
L-TV/L-UA indicates a large tumor volume (≥ 27 mL) and low post-treatment plasma uric acid level (≤301 μmol/L).
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treatment plasma uric acid level above 301 μmol/L had sig-
nificantly better 7-year DMFS (93.7% vs. 66.3%, P <0.001),
PFS (90.5% vs. 77.2%, P = 0.002) and OS rates (97% vs.
86.1% P = 0.026) than patients with post-treatment plasma
uric acid levels equal to or below 301 μmol/L.
Ames et al. [12] reported that uric acid could protect
both erythrocyte membranes and intact erythrocytes
from lysis. Furthermore, uric acid may also protect
longer-lived T and B lymphocytes and macrophages. It is
reasonable to hypothesize that post-treatment plasma
uric acid levels may exert a similar protective effect in
NPC patients, which may provide a mechanism to ex-
plain the relationship between favorable outcome and
high post-treatment plasma uric acid levels observed in
this study. Further studies are needed to fully elucidate
the mechanism by which a high post-treatment plasma
uric acid level is linked to improved survival in NPC pa-
tients receiving IMRT.Table 2 Multivariate analysis of variables correlated with
overall survival in 130 nasopharyngeal cancer patients
treated with IMRT
Variable HR 95% CI P value
Tumor volume, ≥ 27 mL vs. < 27 mL 12.543 1.315-119.641 0.028
Post-treatment uric acid, ≤301 μmol/L vs.
> 301 μmol/L
6.858 2.065-22.775 0.002
N category* 0.908 0.478-1.725 0.768
T category* 1.102 0.506-2.400 0.806
Age, ≤ 45 years vs. > 45 years 0.645 0.254-1.635 0.355
Sex, male vs. female 0.376 0.113-1.251 0.111
HR, hazard ratio; CI, confidence interval; * According to the 7th edition of the
American Joint Committee on Cancer/International Union Against Cancer
staging system.Tumor volume is an important prognostic factor in
cancer patients treated with primary radiotherapy [8]. It
is well accepted that larger tumor volumes represent in-
creased tumor clonogens and a larger hypoxic fraction,
which may directly reduce the efficacy of radiation. Re-
cently, a number of studies have demonstrated the prog-
nostic significance of tumor volume for the evaluation of
local control and OS in patients with NPC [13-16].
However, there have been few reports of the prognostic
significance of tumor volume with respect to distant me-
tastasis. Shen et al. [14] reported that tumor volume was
not associated with the incidence of distant metastasis in
NPC; however, distant failure-free survival was signifi-
cantly related to N-classification, in accordance with
Chua et al. [17]. Our study demonstrated that the 7-year
DMFS, PFS and OS rates in patients with small pre-
treatment tumor volumes (< 27 mL) were significantly
higher than patients with pre-treatment tumor volumes
equal to or larger than 27 mL. In this study, the tumorTable 3 Multivariate analysis of variables correlated with
progression-free survival in 130 nasopharyngeal cancer
patients treated with IMRT
Variable HR 95% CI P value
Tumor volume, ≥ 27 mL vs. < 27 mL 1.540 0.259-9.167 0.635
Post-treatment uric acid, ≤301 μmol/L vs.
> 301 μmol/L
4.852 1.334-17.650 0.017
N category* 1.157 0.570-2.348 0.687
T category* 3.048 1.152-8.068 0.025
Age, ≤ 45 years vs. > 45 years 0.337 0.112-1.014 0.053
Sex, male vs. female 0.748 0.245-2.287 0.611
HR, hazard ratio; CI, confidence interval; * According to the 7th edition of the
American Joint Committee on Cancer/International Union Against Cancer
staging system.
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and the enlarged lymph nodes; whereas Shen et al. [14]
and Chua et al. [17] only included the gross volume of
the primary tumor, and did not include the enlarged
lymph nodes, which may explain the variation in the
results of these studies. This study indicates that pre-
treatment tumor volume is highly significant for the pre-
diction of local control, distant metastasis and overall
survival in NPC patients undergoing IMRT.
Furthermore, by combining the post-treatment plasma
uric acid level and tumor volume, we identified three sub-
groups of patients. The subgroup of patients with a small
pre-treatment tumor volume (< 27 mL) and high post-
treatment plasma uric acid level (>301 μmol/L) had a fa-
vorable prognosis, with a 7-year overall survival rate of
100%. However, the subgroup of patients with a large pre-
treatment tumor volume (≥ 27 mL) and low post-
treatment plasma uric acid level (≤301 μmol/L) had a fairly
poor prognosis, with a 7-year overall survival rate of 48.7%.
This difference might be of clinical importance. The stand-
ard treatment for NPC is radiotherapy with or without
concurrent chemotherapy, which can cure approximately
80% of the patients [18,19]. Our results were consistent
with this, as the 7-year OS, PFS and DMFS rates for the
entire cohort were 81.7%, 87.5% and 91.9%, respectively.
The prognosis for NPC patients who develop metastasis is
generally poor [20]. However, no specific indicator has yet
been identified for this subgroup of patients. In the current
study, we found that the prognosis of patients with a large
pre-treatment tumor volume (≥ 27 mL) and low post-
treatment plasma uric acid level (≤301 μmol/L) was poor,
with a 7-year overall survival of 48.7%. This demonstrates
that combination of the post-treatment plasma uric acid
level and pre-treatment tumor volume has significant
prognostic value in NPC, which may help to determine
the optimal treatment approaches for high risk patients.
Patients with a large tumor volume (≥ 27 mL) and low
post-treatment plasma uric acid level (≤301 μmol/L)
may benefit from newer, more aggressive treatment ap-
proaches, such as adjuvant chemotherapy and additional
accelerated hyperfractionated radiotherapy.
Like many other retrospective studies in the literature,
the interpretation of our results may be hampered by a
number biases. Despite these limitations, the relatively
large number of patients analyzed in this study suggests
that the results are valid. In summary, the current study in-
dicates that the post-treatment plasma uric acid level and
pre-treatment tumor volume have predictive value for the
outcome of NPC patients undergoing IMRT; however,
these results need to be confirmed in larger, prospective
clinical trials. This study indicates that NPC patients with a
large pre-treatment tumor volume (> 27 mL) and low
post-treatment plasma uric acid level (<301 μmol/L)
should receive more aggressive treatment.Competing interests
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